HOPE-Duchenne: A Clinical Trial for Individuals with Heart Disease Related to DMD

Capricor Therapeutics and CureDuchenne hosted a webinar on November 3, 2015. The presentation discussed the HOPE-DUCHENNE Trial. The U.S. Food and Drug Adminstration has cleared Capricor’s Investigational New Drug Application for the clinical development of CAP-1002 for the treatment of patients with Duchenne muscular dystrophy. The webinar provided an overview of the clinical trial which is being conducted at several sites in the U.S.

Click here to watch the recording of the webinar. You’ll be prompted to enter your name and email address to view the recording.